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Adverse Event
Group 1
CABG + AVR
Group 2
PCI + AVR
Group 3
PCI +TAVR p
Death 5 (2.2%) 0 (0%) 0 (0%) 0.41
Acute Kidney Injury 101 (44.9%) 8 (26.7%) 6 (12%) < 0.001
AKIN I 72 (32%) 7 (23.1%) 5 (10%) 0.006
AKIN 2 16 (7.1%) 1 (3.3%) 1 (2%) 0.31
AKIN 3 13 (5.8%) 0 (0%) 0 (0%) 0.09
Acute Myocardial Infarction 41 (18.2%) 2 (6.7%) 5 (10%) 0.13
Q wave 15 (6.7%) 0 (0%) 0 (0%) 0.06
Non Q Wave 26 (11.6%) 2 (6.7%) 5 (10%) 0.71
Neurological events 28 (12.4%) 0 (0%) 4 (8%) 0.09
Surgical wound / puncture site complications 32 (14.2%) 2 (6.7%) 5 (10%) 0.41
Need for transfusions 173 (76.9%) 17 (56.7%) 24 (48%) < 0.001
Packed red blood cells 3.09  3.35 1.53  1.66 1.46  2.37 < 0.001
Fresh frozen plasma 1.65  3.57 0.2  0.81 0.08  0.57 < 0.001
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Background: Use of aspirin plus thienopyridine increases bleeding risk of coronary
artery bypass graft (CABG) surgery. In STOP-CABG trial we prospectively evaluated
the association between the pre-operative platelet function testing by different assay
methods on the occurrence of post CABG bleeding.
Methods: 81 patients undergoing CABG within 5 days of thienopyridine discontin-
uation were prospectively enrolled. On-treatment platelet reactivity was measured
with Verify Now (VN) P2Y12 assay, Vasodilator Stimulated Phosphoprotein Phos-
phorylation (VASP), Light Transmittance Aggregometry (LTA) with 5 and 20 mM of
ADP and MAADP by thrombelastography. The primary endpoint was in-hospital
major bleeding (IHMB).
Results: IHMB occurred in 38 patients (47%). Median VASP PRI (55.2 vs. 62.5,
p¼0.003), LTA ADP 5mM (39 vs. 49, p¼0.002), LTA ADP 20mM (48.5 vs. 65,
p¼0.002) and MA ADP mm (40.4 vs. 50.5, p¼0.03) was signiﬁcantly lower in the
group with IHMB compared to the group with no major bleeding. In a multivariable
logistic regression analysis VASP PRI (OR: 0.96, 95% CI: 0.94-0.99), LTA ADP
5mM (OR: 0.94, 95% CI: 0.91-0.98), LTA ADP 20mM (OR: 0.94, 95% CI: 0.90-0.98)
and MA ADP (OR: 0.96, 95% CI: 0.93-1.00) remained as strong correlates of
IHMB.VN PRU < 198, VASP PRI < 65, LTA ADP 5 mM < 43, LTA ADP
20 mM < 57 and MA ADP < 46 mm were predictive of occurrence of IHMB.Major bleeding present
(Median [IQ range])
Major bleeding absent
(Median [IQ range]) p Value
VN PRU 198 [156-271] 221.5 [195-275] 0.09
VASP PRI 55.2 [25-64] 62.5 [52.5-74.9] 0.003
LTA ADP 5mM 39 [31.5-49] 49 [43-56] 0.002
LTA ADP 20mM 48.5 [43-65.5] 65 [55-72] 0.002
MA ADP (mm) 40.4 [28.5-55.3] 50.5[42-58.8] 0.03Conclusions: On-treatment platelet reactivity testing performed on the day of CABG
surgery is able to predict the occurrence of post-operative IHMB. This may help
clinicians to better manage the timing of CABG after thenopyridine cessation.
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Background: Patients affected by VHD associated to CAD have a poor short-term
prognosis. Even though guidelines recommend traditional valve surgery associated to
CABG, it provides limited beneﬁts and a high incidence of short-term complications.
Less invasive strategies (i.e. hybrid techniques or PCI + TAVR) have been recently
suggested, with interesting results. Aim of our study was to compare the outcomes of
these strategies to standard treatment and to assess the accuracy of risk stratiﬁcation
scores in this setting.
Methods: From 2011 to 2013, 305 patients underwent valve surgery + coronary
revascularization. According to the Heart Team suggestions, 225 pts underwent
CABG + valve surgery (G1), 30 pts PCI + valve surgery (G2) and 50 pts PCI + TAVR
(G3). In each patient we evaluated risk scores (EuroSCORE and STS Score), pro-
cedural data and short-term outcomes. Endpoints were deﬁned as occurrence of
MACE.
Results: Operative risk was similar in G1 (log EuroSCORE: 7.79  6.1) and G2
(5.67  3.82), but it was signiﬁcantly higher in G3 (21.2  13.88). Number of treatedJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Cavessels was 1.57  0.71, 1.3  0.47 and 1.2  0.45, respectively. PCI allowed a
signiﬁcant reduction of operative times (-30’): cross clamp time was 115.68  37.02
min in G1 and 96.13  42.24 in G2 (p 0.008), while ECC time was 150.05  54.87
min vs 120.07  45.94 (p 0.005). Relative Risk for the overall occurrence of a MACE
compared to G1 was 0.46 in G2 (p 0.01) and 0.42 in G3 (p < 0.001).Conclusions: These data prove that in patients affected by VHD and CAD hybrid
strategies are safe and may improve outcomes compared to standard surgery, even in
higher risk patients undergoing TAVR. Thus, we suggest a more extensive use of PCI
combined with valve surgery. Furthermore, we suggest a revision of the current risk
scores, as they were designed upon populations treated with conventional surgery and
can’t ﬁt these new, evolving scenarios.
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Background: Acute kidney injury (AKI) is a well-recognized predictor of morbidity
and mortality following PCI. However, the impact of AKI on the outcome of patients
with acute coronary syndromes (ACS) undergoing coronary artery bypass graft sur-
gery (CABG) has not been established.
Methods: Of the 17,421 patients who presented with non-ST-segment elevation
ACS or ST-segment elevation myocardial infarction (STEMI) enrolled in the
ACUITY and the HORIZONS-AMI trials, 1,406 (8.0%) underwent CABG as
principal treatment after coronary angiography. Endpoints were measured at 1 month
and 1 year and included death, MI and ischemia-driven target vessel revasculariza-
tion (TVR).
Results: AKI occurred during hospital admission in 449 (31.9%) of the 1,406 patients
treated with CABG. Patients with vs. without AKI had 1-month and 1-year mortality
of 6.7% vs. 2.2%, p< 0.0001, and 10.4% vs. 4.3%, p< 0.0001, respectively. Patients
with vs. without AKI had 1-month and 1-year composite major adverse cardiac events
(MACE; death, MI or TVR) of 21.2% vs. 14.8%, p¼0.003, and 22.0% vs. 15.3%,
p¼0.002, respectively. By multivariable analysis, after adjustment for age, gender,
race, diabetes, hypertension, and baseline creatinine clearance, AKI was an inde-
pendent predictor of mortality (overall and cardiac-related), as well as MACE at both
1 month and 1 year following CABG (Figure).Conclusions: AKI occurs in w1 of every 3 patients with ACS treated with CABG,
and is a powerful independent predictor of death and MACE. These data highlight the
need for AKI prevention strategies in patients undergoing CABG.rdiac and Vascular Surgery B37
